{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:10:36Z","timestamp":1792548636540,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006578","name":"Chi Mei Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10557-024-07620-x","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T06:02:38Z","timestamp":1729490558000},"page":"1405-1416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"Mei-Chuan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Te","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Siong","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chuan","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6532-1169","authenticated-orcid":false,"given":"Hui-Chen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"7620_CR1","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712\u201323. https:\/\/doi.org\/10.1182\/blood-2013-04-460121.","journal-title":"Blood"},{"issue":"Supplement","key":"7620_CR2","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","volume":"141","author":"C Kearon","year":"2012","unstructured":"Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(Supplement):e419S \u2013 e496. https:\/\/doi.org\/10.1378\/chest.11-2301.","journal-title":"Chest"},{"key":"7620_CR3","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484\u20138. https:\/\/doi.org\/10.1182\/blood-2002-01-0108.","journal-title":"Blood"},{"key":"7620_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.9243","volume":"314","author":"AYY Lee","year":"2015","unstructured":"Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314:677\u201386. https:\/\/doi.org\/10.1001\/jama.2015.9243.","journal-title":"JAMA"},{"key":"7620_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146\u201353. https:\/\/doi.org\/10.1056\/NEJMoa025313.","journal-title":"N Engl J Med"},{"key":"7620_CR6","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","volume":"17","author":"D Farge","year":"2016","unstructured":"Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(16)30369-2.","journal-title":"Lancet Oncol"},{"key":"7620_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1160\/TH12-03-0169","volume":"108","author":"SR Kahn","year":"2012","unstructured":"Kahn SR, Springmann V, Schulman S, Martineau J, Stewart JA, Komari N, et al. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The recovery study. Thromb Haemost. 2012;108:493\u20138. https:\/\/doi.org\/10.1160\/TH12-03-0169.","journal-title":"Thromb Haemost"},{"key":"7620_CR8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jacc.2008.05.042","volume":"52","author":"D Hu","year":"2008","unstructured":"Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol. 2008;52:865\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2008.05.042.","journal-title":"J Am Coll Cardiol"},{"key":"7620_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405.","journal-title":"Eur Heart J"},{"key":"7620_CR10","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.2174\/1381612826666200420150517","volume":"26","author":"PE Papakonstantinou","year":"2020","unstructured":"Papakonstantinou PE, Tsioufis C, Konstantinidis D, Iliakis P, Leontsinis I, Tousoulis D. Anticoagulation in deep venous thrombosis: current trends in the era of non-vitamin K antagonists oral anticoagulants. Curr Pharm Des. 2020;26:2692\u2013702. https:\/\/doi.org\/10.2174\/1381612826666200420150517.","journal-title":"Curr Pharm Des"},{"key":"7620_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1302507.","journal-title":"N Engl J Med"},{"key":"7620_CR12","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"Hokusai-VTE Investigators, B\u00fcller HR, D\u00e9cousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1306638.","journal-title":"N Engl J Med"},{"key":"7620_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-9560-11-21","volume":"11","author":"MH Prins","year":"2013","unstructured":"Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral Rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21. https:\/\/doi.org\/10.1186\/1477-9560-11-21.","journal-title":"Thromb J"},{"key":"7620_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","volume":"129","author":"S Schulman","year":"2014","unstructured":"Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.004450.","journal-title":"Circulation"},{"key":"7620_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.6004\/jnccn.2021.0047","volume":"19","author":"MB Streiff","year":"2021","unstructured":"Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease. version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw JNCCN. 2021;19:1181\u2013201. https:\/\/doi.org\/10.6004\/jnccn.2021.0047.","journal-title":"J Natl Compr Canc Netw JNCCN"},{"key":"7620_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/rth2.12359","volume":"4","author":"F Moik","year":"2020","unstructured":"Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost. 2020;4:550\u201361. https:\/\/doi.org\/10.1002\/rth2.12359.","journal-title":"Res Pract Thromb Haemost"},{"key":"7620_CR17","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2020005819","volume":"136","author":"FI Mulder","year":"2020","unstructured":"Mulder FI, Bosch FTM, Young AM, Marshall A, McBane RD, Zemla TJ, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020;136:1433\u201341. https:\/\/doi.org\/10.1182\/blood.2020005819.","journal-title":"Blood"},{"key":"7620_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1378\/chest.14-0402","volume":"147","author":"MC Vedovati","year":"2015","unstructured":"Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015;147:475\u201383. https:\/\/doi.org\/10.1378\/chest.14-0402.","journal-title":"Chest"},{"key":"7620_CR19","doi-asserted-by":"publisher","first-page":"CD006650","DOI":"10.1002\/14651858.CD006650.pub5","volume":"6","author":"LA Kahale","year":"2018","unstructured":"Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6:CD006650. https:\/\/doi.org\/10.1002\/14651858.CD006650.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"7620_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clin Res Ed). 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ (Clin Res Ed)"},{"key":"7620_CR21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed). 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ (Clin Res Ed)"},{"key":"7620_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"7620_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed). 2003;327:557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ (Clin Res Ed)"},{"key":"7620_CR24","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"7620_CR25","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (Clin Res Ed). 2011;343:d4002. https:\/\/doi.org\/10.1136\/bmj.d4002.","journal-title":"BMJ (Clin Res Ed)"},{"key":"7620_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.013.","journal-title":"J Clin Epidemiol"},{"key":"7620_CR27","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jth.13153","volume":"13","author":"G Agnelli","year":"2015","unstructured":"Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187\u201391. https:\/\/doi.org\/10.1111\/jth.13153.","journal-title":"J Thromb Haemost"},{"key":"7620_CR28","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1915103.","journal-title":"N Engl J Med"},{"key":"7620_CR29","doi-asserted-by":"publisher","unstructured":"Kim JH, Yoo C, Seo S, Jeong JH, Ryoo BY, Kim KP, et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers (Basel). 2022;14(3):559. https:\/\/doi.org\/10.3390\/cancers14030559.","DOI":"10.3390\/cancers14030559"},{"key":"7620_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18:411\u201321. https:\/\/doi.org\/10.1111\/jth.14662.","journal-title":"J Thromb Haemost"},{"key":"7620_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","volume":"161","author":"B Planquette","year":"2022","unstructured":"Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mah\u00e9 I, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161:781\u201390. https:\/\/doi.org\/10.1016\/j.chest.2021.09.037.","journal-title":"Chest"},{"key":"7620_CR32","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","volume":"1","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral Rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1:e37-46. https:\/\/doi.org\/10.1016\/S2352-3026(14)70018-3.","journal-title":"Lancet Haematol"},{"key":"7620_CR33","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","volume":"3","author":"GE Raskob","year":"2016","unstructured":"Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016;3:e379\u201387. https:\/\/doi.org\/10.1016\/S2352-3026(16)30057-6.","journal-title":"Lancet Haematol"},{"key":"7620_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1711948.","journal-title":"N Engl J Med"},{"key":"7620_CR35","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","volume":"329","author":"D Schrag","year":"2023","unstructured":"Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329:1924\u201333. https:\/\/doi.org\/10.1001\/jama.2023.7843.","journal-title":"JAMA"},{"key":"7620_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1160\/TH14-11-0977","volume":"114","author":"S Schulman","year":"2015","unstructured":"Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. 2015;114:150\u20137. https:\/\/doi.org\/10.1160\/TH14-11-0977.","journal-title":"Thromb Haemost"},{"key":"7620_CR37","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017\u201323. https:\/\/doi.org\/10.1200\/JCO.2018.78.8034.","journal-title":"J Clin Oncol"},{"key":"7620_CR38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/1708538120971148","volume":"29","author":"ME Mokadem","year":"2021","unstructured":"Mokadem ME, Hassan A, Algaby AZ. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular. 2021;29:745\u201350. https:\/\/doi.org\/10.1177\/1708538120971148.","journal-title":"Vascular"},{"key":"7620_CR39","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1200\/JCO.2005.03.133","volume":"23","author":"AY Lee","year":"2005","unstructured":"Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23:2123\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.03.133.","journal-title":"J Clin Oncol"},{"key":"7620_CR40","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902\u20137. https:\/\/doi.org\/10.1182\/blood-2007-10-116327.","journal-title":"Blood"},{"key":"7620_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/sj.neo.7900263","volume":"4","author":"GJ Caine","year":"2002","unstructured":"Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4:465\u201373. https:\/\/doi.org\/10.1038\/sj.neo.7900263.","journal-title":"Neoplasia"},{"key":"7620_CR42","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","volume":"73","author":"RC Mosarla","year":"2019","unstructured":"Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;73:1336\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.017.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"7620_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355.","journal-title":"Circulation"},{"issue":"41","key":"7620_CR44","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"key":"7620_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","volume":"53","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120\u20137. https:\/\/doi.org\/10.1016\/j.ctrv.2016.12.002.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"7620_CR46","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1182\/bloodadvances.2018016683","volume":"2","author":"S Yamshon","year":"2018","unstructured":"Yamshon S, Christos PJ, Demetres M, Hammad H, Leonard JP, Ruan J. Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis. Blood Adv. 2018;2(12):1429\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2018016683.","journal-title":"Blood Adv"},{"issue":"13","key":"7620_CR47","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","volume":"28","author":"TK Choueiri","year":"2010","unstructured":"Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28(13):2280\u20135. https:\/\/doi.org\/10.1200\/JCO.2009.27.2757.","journal-title":"J Clin Oncol"},{"key":"7620_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M22-1258","volume":"176","author":"S Gulati","year":"2023","unstructured":"Gulati S, Eckman MH. Anticoagulant therapy for cancer-associated thrombosis: a cost-effectiveness analysis. Ann Intern Med. 2023;176:1\u20139. https:\/\/doi.org\/10.7326\/M22-1258.","journal-title":"Ann Intern Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07620-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07620-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07620-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:00:42Z","timestamp":1766127642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07620-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7620"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07620-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"15 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review did not involve any human or animal subjects; therefore, ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}